Treatment and clinical outcomes of patients relapsing after allogeneic hematopoietic cell transplantation for myelodysplastic syndrome

BACKGROUND: Although allogeneic hematopoietic cell transplantation (HCT) is the only curative treatment option for myelodysplastic syndrome (MDS), a substantial number of patients experience relapse. We reviewed the clinical outcomes of patients with MDS who relapsed after allogeneic HCT. METHODS: T...

Descripción completa

Detalles Bibliográficos
Autores principales: Choi, Eun-Ji, Lee, Je-Hwan, Lee, Jung-Hee, Park, Han-Seung, Ko, Sun-Hye, Seol, Miee, Lee, Young-Shin, Kang, Young-Ah, Jeon, Mijin, Lee, Kyoo-Hyung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Society of Hematology; Korean Society of Blood and Marrow Transplantation; Korean Society of Pediatric Hematology-Oncology; Korean Society on Thrombosis and Hemostasis 2018
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6300680/
https://www.ncbi.nlm.nih.gov/pubmed/30588465
http://dx.doi.org/10.5045/br.2018.53.4.288

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6300680/
https://www.ncbi.nlm.nih.gov/pubmed/30588465
http://dx.doi.org/10.5045/br.2018.53.4.288

Ejemplares similares